Nanobiotix S.A. - ADSs (NBTX) Stock

About Nanobiotix S.A. - ADSs

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

Nanobiotix S.A. - ADSs (NBTX) stock trades at $29.36 with a market capitalization of $1.47B. The stock is valued at a negative price-to-earnings (P/E) ratio of -20.31, reflecting a net loss over the last twelve months, a negative price-to-book of -32.71, reflecting negative shareholders' equity, price-to-sales of 132.65. Over the past 52 weeks the stock has ranged between $14.78 and $57.14, and currently trades 48.6% below its 52-week high.

On profitability, Nanobiotix S.A. - ADSs generates a return on equity (ROE) of 89.71% (not meaningful, as shareholders' equity is negative), return on capital employed of -110.00%, an operating margin of -36.67%, a net profit margin of -617.88%.

Official website: www.nanobiotix.com

Nanobiotix S.A. - ADSs by the numbers, 2016–2025

Between 2016 and 2025 Nanobiotix S.A. - ADSs reported revenue of $5.0M rising to $30.0M, a change of +500.0% across 10 years. Compounded, revenue has grown 71.9% a year over five years, 81.7% over three, —% over the last twelve months. Net profit fell to $-24.0M.

Operating margin went from -403.1% in 2016 to -36.5% in 2025, a gain of 366.6 percentage points. The most recent net margin is -617.88%. On a trailing twelve-month basis to Jun '26, revenue is $18.0M and net profit $-105.0M.

Borrowings rose from $6.0M to $95.0M, cash from operations was $-33.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 433.7% over five years, and was 28.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Nanobiotix S.A. - ADSs (NBTX) — frequently asked questions